Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × NOV 002 × Clear all
NCT00345540 2015-03-10

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

Cellectar Biosciences, Inc.

Phase 2 Completed
15 enrolled 8 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡